Aided by mice with multiple deleted brain matrix protein genes, the biochemical analysis of mouse brain matrix molecules indicates a constitutive production of more proteoglycans than can be integrated in multimolecular matrix structures. Possible functions of non-matrix integrated proteoglycans, and aspects of incomplete compensatory mechanisms in knockout mice are discussed.
brain they appear to co-distribute with versican and brevican respectively [9, 10] (Figure 1A) . Interestingly, the deposition, but not the expression of Bral2 is reduced in brevicandeficient mice [9] . This observation further supports the presence of ternary complexes of hyaluronan aggregates of lecticans and link proteins in the CNS. A fourth apparently non-neuronal member of the link protein family co-localizes with versican in smooth muscle tissue [11] .
While the N-terminal domains of aggregated lecticans are engaged in hyaluronan and link protein binding, the C-terminal domains would provide suitable binding sites for other molecules in the CNS extracellular environment. Two secreted matrix molecules that are present there and can interact with these domains are tenascin-R and -C ( Figure 1A ). Owing to their oligomeric nature, these tenascins would even be able to interconnect hyaluronate aggregates. Both, tenascin-C and -R, can bind to the C-terminal domain of all four mammalian lecticans, although with varying degrees of affinity [12] (Figure 1A) . A very low affinity has been determined for the interaction of brevican with tenascin-C, but due to tenascin-C's hexameric structure and potential to increase the avidity, this interaction might also be of significance. On the other hand, tenascins do not depend on lectican-binding sites for their integration into the extracellular environment, because they can also bind to various other extracellular matrix and cell surface molecules. Thus tenascins, especially tenascin-R, could serve as cell surface anchors for lecticans, or even lectican-hyaluronan aggregates. Interactions of the remaining members of the tenascin protein family with lecticans have not been reported. Tenascin-X interacts with fibrillar collagens, which are not apparent in the CNS. Least characterized for any binding abilities are the most recently identified mouse tenascin-N and mouse tenascin-W, which have essentially the same sequence, except for an insertion of three additional fibronectin type III repeats in the tenascin-N sequence [13, 14] . While tenascin-N was observed in the CNS, tenascin-W was not.
Turnover
At early postnatal stages of rodent brain development, chondroitin sulfate proteoglycans, and neurocan in particular, are very abundantly present in brain tissue [15, 16] . During the first postnatal month a high turnover of sulfated glycosaminoglycans, in particular type A and C chondroitin sulfate structures, as high as 90% in 24 h, has been reported [17] . Such intensive remodelling appears surprising, and hardly agrees with a model considering proteoglycan aggregates as the core components of basic extracellular matrix structures of the CNS. Moreover, even though it is very likely that aggregates as proposed above exist, it renders their functional importance quite questionable. However, there is the possibility of accommodating a high turnover rate with a basic structural function of proteoglycans. It would assume an extensive overproduction of proteoglycans, oversaturating all potential binding sites, and a consecutive turnover of the non-matrix integrated material.
Our studies with mouse strains lacking one or several components of the brain extracellular matrix indicate that there indeed might be an overproduction of proteoglycans, and that the amount of proteoglycans maintained in the tissue is more dependent on the availability of potential anchoring sites than on the number of molecules produced. In 1-monthold mice tenascin-C and -R appear to contribute almost exclusively to the potential anchoring sites for neurocan or the C-terminal fragment of neurocan, which is at this developmental stage mostly proteolytically processed. In the brain of mice lacking these two molecules, two other extracellular matrix molecules, fibulin-1 and -2, are highly abundant [18] . Although they appear to be able to compensate for many of the activities of tenascin-C and tenascin-R, they are not able to interact with neurocan [19] (Figure 1C ). This situation provided the opportunity to monitor the effect of the elimination of anchoring sites on the concentration of a major matrix proteoglycan in vivo.
In 1-month-old mice that are lacking brevican, the concentration of neurocan was found to be much higher than in wild-type animals, although neurocan mRNA levels were similar [20] (Figure 2A ). Brevican is likely to compete with neurocan for binding sites in the extracellular environment. Tenascin-R in particular, which is the dominant tenascin at this relatively late developmental stage, has a higher affinity for brevican than for neurocan ( Figure 1A) . Thus, in the presence of brevican, even an extensive overproduction of neurocan would probably only marginally affect its ability to be maintained in the matrix, while in the absence of brevican many binding sites, which are usually occupied by this molecule, would be available ( Figures 1D and 1E) .
In mice lacking two extracellular matrix molecules, brevican and tenascin-R, thus lacking a competitor and an anchoring site simultaneously, the concentration of neurocan is similar to wild-type mice. The concentration of tenascin-C in mice lacking tenascin-R appears somewhat increased, although not as obvious as the concentration of neurocan in brevican single KO (knockout) mice ( Figure 2B ). However, since neurocan has a higher affinity for tenascin-C than for tenascin-R, even a modest amount of additional tenascin-C could substitute for the loss of the fraction of tenascin-R-binding sites, which would be occupied by neurocan in wild-type mice ( Figures 1D and 1F) . In mice lacking brevican, tenascin-R and tenascin-C, the concentration of neurocan is obviously much lower than in wild-type mice (Figure 2A) . Taken together, these observations indicate that more neurocan is produced than needed, and that the difference between the amounts of neurocan found in the brevican single KO and the brevican/tenascin-C/R triple KO mice would reflect material exceeding the saturation of the binding sites and being subjected to turnover.
Interestingly, neurocan was discovered as a prominent component of the water-soluble, and therefore easily accessible fraction of chondroitin sulfate proteoglycans in rat brain [16] . Thus it is tempting to speculate that these proteoglycans are easy to extract because they are not integrated in any structural matrix. They might just represent an overproduction of these molecules, exceeding the number of binding sites, which
Recently, it has been shown in neuronal cultures that the addition of soluble proteoglycans of the lectican family alters tenascin-R-induced changes in the morphology of axons [21] . Tenascin-R can interact with the cell-adhesion molecule contactin-1 in the axonal membrane, and thereby mediate the induction of microspikes along the axon [22] . The binding site of tenascin-R for contactin-1 has been mapped to the second and third fibronectin type III repeats of tenascin-R [23] . This is very close to and probably overlapping with the binding site of the C-type lectin domain of lecticans, which bind mainly to the 4th fibronectin type III repeat of tenascin-R [24] . Therefore, an excess of lecticans could compete out contactin-1 as a tenascin-R ligand. Thus a function of soluble, not matrix integrated proteoglycans could be the regulation of interactions of tenascins with contactin and other cellular receptors. Moreover, besides the interaction of tenascin-R with contactin-1, neurocan has been shown to modulate other interactions of cell-adhesion molecules also directly, such as the homophilic interactions of NCAM (neural celladhesion molecule) and L1 (reviewed in [25] ). These activities can actually be mediated just by C-terminal fragments of neurocan. In analogy, C-terminal fragments of lecticans appear to be as suitable to compete with contactin-1 as the entire molecule. Such fragments might be even more potent, since they are probably less restricted in their diffusion through the extracellular environment. Neurocan is developmentally increasingly proteolytically processed [16] . Thus the fragmentation of neurocan coincides with decreasing neurite growth and cellular migrations, events that are commonly associated with the activity of cell-adhesion molecules.
In contrast with all other lecticans, which are proteolytically processed by ADAMTS (a disintegrin and metalloprotease with thrombospondin motifs) molecules, the proteolytic cleavage of neurocan has been proposed to be mediated by MMP2 (matrix metalloproteinase 2; reviewed in [26] ) ( Figure 1B ). This suggestion is mainly based on a comparison of the amino acid sequence around the well-known proteolytic cleavage site of neurocan with a library of known cleavage sites of individual proteases [27] . Although neurocan has been shown to be sensitive to MMP2, clear evidence that MMP2 cleaves at the identical site at which neurocan is cleaved in vivo, has not been presented. We have generated an antiserum against the known N-terminal amino acid sequence of the C-terminal neurocan fragment. This antiserum detects the C-terminal fragment considerably better than the uncleaved molecule. Interestingly, this antiserum raised against the common rodent sequence did also recognize the human C-terminal neurocan fragment, although the sequence of human neurocan shows some mismatches in the amino acid sequence. This cross-reactivity allowed the detection of neurocan in samples of human gliomas, brain tumours, which are often associated with MMP2 activity. Recently, in addition to MMP2, ADAMTS proteases have also been implicated in human brain tumour progression [28] . Thus ADAMTS proteases could be responsible for the observed fragmentation of neurocan in brain tumours as well. In human cerebrospinal fluid samples, the neoepitope antiserum did not detect neurocan, although in these samples fragments of the appropriate size could be detected with an antiserum raised against the entire neurocan molecule. This was surprising, since MMP2 appears to be a constitutive component of cerebrospinal fluid [29] . Thus the question of which protease or proteases are responsible for the proteolytic processing of neurocan, may not be finally resolved.
Necessity
Attempts to demonstrate the importance of brain extracellular matrix molecules by deletion mutants in mice are overshadowed by the observation of unexpectedly mild phenotypes. This might not be surprising for some, since it is consistent with the idea that mice have been intelligently designed to multiply themselves efficiently to serve as experimental models for researchers and to provide food for reptiles and birds, and not to develop sophisticated strategies to escape their fate. Others might not be surprised, because many brain molecules are members of protein families which could substitute for each other's basic function, and, in particular in the brain, often more than one member of protein families are present. Thus the first candidates to look at in order to compensate for a deletion of a molecule are commonly homologous members of the same family. One example is the apparent compensation of a lack of brevican by an increased deposition of neurocan [20] . However, neurocan might be able to compensate for some structural, but not for all functional deficits caused by brevican elimination. This is apparent from the severely reduced long-term potentiation, a model for investigating cellular and molecular mechanism for memory formation and storage, in brevican KO mice [20] . The compensation for the elimination of both lecticans, neurocan and brevican, would be expected to be mainly mediated by an increased deposition of the remaining brain-resident members of the family, versican and aggrecan. However, owing to the larger and heterogeneous size of these highly glycosylated molecules, it is more difficult to obtain convincing experimental evidence for this.
The deletion of the tenascins tenascin-C and -R, and actually even the deletion of tenascin-R alone, mediated the increased deposition of fibulin-1 and -2, molecules belonging to a different glycoprotein family, although other tenascins exist [18] . While tenascin-X appears to be a collagen fibril-binding, non-CNS molecule, tenascin-N, but interestingly not tenascin-W, has been observed in mouse brain, especially at more mature developmental stages [13, 14] . It should be noted that these studies were performed with antisera prepared against different parts of the fibronectin type III repeat-containing region of the molecule, a region highly susceptible to alternative splicing. Since tenascin-N/W resides in the human genome very close to tenascin-R, it will be interesting to see whether it shares, in addition to the locus, ligands with tenascin-R, and whether it is up-regulated in tenascin-R KO mice as well.
Functionally fibulin-1 and -2 are related to tenascin, since they are able to interact with the C-terminal domains of versican and aggrecan, but curiously not neurocan [19] . However, although the loss of neurocan from brains lacking tenascin-C and -R appears to be a clear logical consequence of its binding potential, it cannot be excluded that the presence of fibulin-1 enhances its proteolytic degradation, since it has been shown that fibulin-1 enhances the activity of ADAMTS-proteases [30] . Fibulins appear to be generally designed to aid in the assembly of a temporary extracellular environment. Fibulin-1 and -2 are expressed during the developmental transition phases of many organs, for example, in the endocardial cushion tissue, and are up-regulated in wound tissue (reviewed in [31] ). Recently, the deposition of fibulin-2 in artherosclerotic plaques was observed [32] . Fibulin-1 can be detected at relatively high concentrations in blood serum. In normal mouse brain fibulin-1 deposition is restricted to vascular and meningeal structures [18] .
In the absence of tenascin-R, fibulins could be up-regulated in brain, either because they can functionally substitute for tenascin-R or because they would be up-regulated in any tissue in cases of emergency, where the extracellular matrix appears to need to be supported. Although it is probably not possible to answer this question, the deposition of fibulins indicates that the absence of tenascins in brain could be considered a chronic emergency.
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